Overweight and obesity among children and adolescents continue to be a global public health epidemic. Current national data on childhood and adolescent obesity show alarming statistics of overweight and obese children and adolescents. This epidemic runs across various continents and affects various ethnic populations. The current weight management practices involve dietary modification, behavioral change therapies involving exercise, pharmacological therapy and surgical intervention. The purpose of this current review is to focus on pharmacological therapy i.e. role of sibutramine and orlistat in childhood and adolescent weight management. An open search of PUBMED database was made with search ‘key words’ such as ‘orlistat’ or ‘sibutramine’ or “pharmacological approaches” and “child obesity” and “adolescent obesity”. This yielded a total of 20 articles. All of these articles have been summarized in the current review. Sibutramine functions by promoting satiety and increases energy expenditure by inhibiting reuptake of noradrenaline and serotonin. Most of the studies, reviews and trials conducted using sibutramine among adolescents and children show limited short-term efficacy. The long-term effects of sibutramine use are not yet studied due to the severity of its side-effects profile. Orlistat was approved by Food and Drug Administration for adolescent weight reduction. Despite its approval, it has a limited role in adolescent and pediatric obesity reduction due to the purported malabsorption of fat soluble vitamins and its side-effect profile. Obesity and adolescent weight management in present times mainly deals with dietary modification with superadded behavioral therapies promoting exercise. There is insufficient evidence as of now if these alone would cause adequate weight reduction and weight maintenance. Pharmacotherapy i.e use of drugs like sibutramine and orlistat has a limited role in the current fight against childhood and adolescent obesity. Extreme side-effects, close monitoring and lack of long-term studies involving these drugs, suggest questionable efficacy in current times. Future research studies involving pharmacological agents need to not only have immense scientific rigor during preliminary analyses but should also translate their efficacy in practical and clinical settings.doi:10.4021/jocmr2010.05.288w
展开▼
机译：儿童和青少年中的超重和肥胖仍然是全球公共卫生流行病。有关儿童和青少年肥胖的最新国家数据显示，超重和肥胖儿童和青少年的统计数字令人震惊。这种流行病遍及各大洲，并影响着各个种族。当前的体重管理做法涉及饮食调整，涉及运动的行为改变疗法，药物治疗和外科手术干预。本篇综述的目的是着重于药物治疗，即西布曲明和奥利司他在儿童和青少年体重管理中的作用。使用“奥利司他”或“西布曲明”或“药理学方法”以及“儿童肥胖症”和“青少年肥胖症”等“关键词”进行开放式PUBMED数据库搜索。这总共产生了20篇文章。所有这些文章已在当前的评论中进行了总结。西布曲明通过促进饱腹感起作用，并通过抑制去甲肾上腺素和5-羟色胺的再摄取而增加能量消耗。在青少年和儿童中使用西布曲明进行的大多数研究，评价和试验均显示出有限的短期疗效。由于西布曲明副作用的严重性，尚未对其长期使用效果进行研究。 Orlistat已获得美国食品药品监督管理局（Food and Drug Administration）批准，可减轻青少年体重。尽管已获得批准，但由于据称脂溶性维生素吸收不良及其副作用，在减少青少年肥胖症和降低儿童肥胖方面作用有限。当前的肥胖和青少年体重管理主要涉及通过增加行为疗法促进运动的饮食调节。到目前为止，没有足够的证据证明仅这些因素就能减轻体重并保持体重。药物疗法，例如西布曲明和奥利司他等药物的使用在当前对抗儿童和青少年肥胖的斗争中作用有限。极端的副作用，密切的监测以及缺乏涉及这些药物的长期研究表明，目前的疗效令人怀疑。未来涉及药理学的研究不仅需要在初步分析期间具有巨大的科学严谨性，而且还应在实际和临床环境中转化其功效。doi：10.4021 / jocmr2010.05.288w
展开▼
